协生菌对改善2型糖尿病的效果超过单独的益生菌:一个随机,双盲,安慰剂控制的试验
Chao Zhang1, Qi Zhang1, Xiaoxu Zhang1
1Department of Nutrition and Health, Key Laboratory of Functional Dairy, Co-constructed by Ministry of Education and Beijing Government, China Agricultural University, Beijing 100193, China.
Clinical nutrition (Edinburgh, Scotland)
|December 25, 2024
概括
协生菌 (益生菌+益生菌) 在2型糖尿病患者的禁食血糖 (FBG) 显著降低,远远超过单独使用益生菌. 这表明共生菌可以通过肠道微生物群调节来改善血糖控制.
科学领域:
- 微生物学 微生物学
- 内分泌学 在内分泌学.
- 营养科学 营养科学
背景情况:
- 综合生物,结合益生菌和益生菌,为管理2型糖尿病 (T2DM) 提供了潜在的协同方法.
- 在T2DM中,协生菌与益生菌的比较疗效需要进一步研究.
- 本研究评估了一种特定的协生菌 (MN-Gup-GOS) 和益生菌 (MN-Gup) 用于T2DM患者的血糖控制.
研究的目的:
- 为了评估Bifidobacterium animalis亚种的影响. 乳糖MN-Gup (MN-Gup) 和一个共生混合物 (MN-Gup-GOS) 对T2DM患者的血糖控制.
- 探索潜在的机制,包括对炎症,氧化应激,肠道微生物群和胃肠道激素的影响.
- 为了比较协生菌与单独益生菌在改善血糖指标方面的疗效.
主要方法:
- 一个为期12周的随机,双盲,安慰剂对照试验,涉及120名T2DM患者.
- 干预包括MN-Gup,MN-Gup-GOS或安慰剂.
- 主要结局:空腹血糖 (FBG);次要结局:HbA1C,胰岛素,HOMA-IR,炎症标志物,氧化应激,肠道激素,微生物群和胆汁酸.
主要成果:
- 所有组都显示FBG减少;然而,MN-Gup-GOS显著减少了FBG,比安慰剂和MN-Gup.
- 在MN-Gup-GOS组中,HbA1c,胰岛素和HOMA-IR显著下降.
- 无论是MN-Gup还是MN-Gup-GOS都调节了炎症,氧化应激,肠道微生物群,胆汁酸和GLP-1,MN-Gup-GOS的效果更大.
结论:
- 与单独使用益生菌 (MN-Gup) 相比,合成生物 (MN-Gup-GOS) 在T2DM患者中在减少FBG方面表现出更高的疗效.
- 增强的血糖控制可能归因于协生菌对肠道微生物群,胆汁酸和GLP-1分泌的更大调节.
- 这些发现支持协生菌作为治疗2型糖尿病的辅助疗法的潜力.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Management and Pharmacotherapy
203
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
203
Oral Hypoglycemic Agents: Biguanides and Glitazones
132
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
Carbohydrate Metabolism
10.5K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.5K
Oral Hypoglycemic Agents: Sulfonylureas
153
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
153
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K


